Switch to:
GuruFocus has detected 3 Warning Signs with Allergan PLC $AGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Allergan PLC (NYSE:AGN)
Research & Development
$2,933 Mil (TTM As of Mar. 2017)

This is the expense the company spent on research and development. Allergan PLC's research and development for the three months ended in Mar. 2017 was $760 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2017 was $2,933 Mil.


Definition

This is the expense the company spent on research and development.

Allergan PLC Research & Development for the trailing twelve months (TTM) ended in Mar. 2017 was 636.5 (Jun. 2016 ) + 622.8 (Sep. 2016 ) + 913.3 (Dec. 2016 ) + 759.9 (Mar. 2017 ) = $2,933 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Allergan PLC Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
Research & Development 1451701972963074031916062,3592,576

Allergan PLC Quarterly Data

Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16Mar17
Research & Development 2373183501,261431403637623913760
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK